Compare ARK Genomic Revolution ETF (ARKG) vs KLA Corp. (KLAC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs KLA Corp. — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while KLA Corp. trades at $225 (market cap $302.43B). The key difference: KLA Corp. pays a 0.4% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, KLA Corp. nearer its low. Which is the better fit depends on your goals.
| ARKG | KLAC | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $301.71 |
52-Week Low | $23.09 | $84.39 |
Market Cap | — | $302.43B |
Enterprise Value | — | $303.62B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
KLA Corporation (KLAC) trades at $231.52, up 0.88% on the day, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.94 exceeding the $0.917 estimate. Revenue grew to $12.16 billion in 2025, driving a net income margin of 35.66%. A 1:10 stock split is scheduled for June 12, 2026, and a $2.30 dividend was paid in June 2026.
KLAC's outlook is supported by AI-driven semiconductor equipment demand and consistent earnings outperformance, but high valuation ratios (P/E 65.57, P/S 23.38) pose risks if growth slows. Analysts maintain a buy consensus with a $239.86 price target, though competitive pressures and market volatility remain concerns for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
